Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crinecerfont - Neurocrine Biosciences

Next Previous
Drug Profile

Crinecerfont - Neurocrine Biosciences

Alternative Names: CRENESSITY; NBI-74788; SSR-125543; SSR-125543A

Latest Information Update: 16 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Developer Neurocrine Biosciences; Sanofi
  • Class Amines; Antidepressants; Anxiolytics; Chlorobenzenes; Cyclopropanes; Fluorobenzenes; Halogenated hydrocarbons; Phenyl ethers; Small molecules; Thiazines; Thiazoles
  • Mechanism of Action Corticotropin releasing factor receptor 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital adrenal hyperplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Congenital adrenal hyperplasia
  • Discontinued Major depressive disorder; Post-traumatic stress disorders

Most Recent Events

  • 14 Jul 2025 Pooled efficacy data from the phase III CAHtalyst Adult and CAHtalyst Paediatric trials in Congenital adrenal hyperplasia released by Neurocrine Biosciences
  • 14 Jul 2025 Updated efficacy data from the phase III CAHtalyst Adult trial in Congenital adrenal hyperplasia released by Neurocrine Biosciences
  • 16 May 2025 Upated efficacy data from the phase III CAHtalyst Paediatric trial in Congenital adrenal hyperplasia released by Neurocrine Biosciences

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top